Journal Articles
2019

Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence
and Clinical Observations
S. Elhosseiny
H. Al Moussawi
J. M. Chalhoub
J. Lafferty
Zucker School of Medicine at Hofstra/Northwell, jlafferty1@northwell.edu

L. Deeb
Zucker School of Medicine at Hofstra/Northwell, ldeeb1@northwell.edu

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Gastroenterology Commons

Recommended Citation
Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct Oral Anticoagulants in Cirrhotic
Patients: Current Evidence and Clinical Observations. . 2019 Jan 01; 2019():Article 5103 [ p.]. Available
from: https://academicworks.medicine.hofstra.edu/articles/5103. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Hindawi
Canadian Journal of Gastroenterology and Hepatology
Volume 2019, Article ID 4383269, 8 pages
https://doi.org/10.1155/2019/4383269

Review Article
Direct Oral Anticoagulants in Cirrhotic Patients:
Current Evidence and Clinical Observations
Sherif Elhosseiny ,1 Hassan Al Moussawi,1 Jean M. Chalhoub,1
James Lafferty,2 and Liliane Deeb3
1

The Department of Medicine at Staten Island University Hospital, Northwell Health, USA
The Department of Cardiology at Staten Island University Hospital, Northwell Health, USA
3
The Department of Gastroenterology at Staten Island University Hospital, Northwell Health, USA
2

Correspondence should be addressed to Sherif Elhosseiny; selhossein@northwell.edu
Received 22 July 2018; Revised 17 December 2018; Accepted 26 December 2018; Published 8 January 2019
Academic Editor: Kevork M. Peltekian
Copyright © 2019 Sherif Elhosseiny et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel
convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic
therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered
hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with
cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and
safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation
options in patients with cirrhosis and their safety profile.

1. Background
Vitamin K antagonists (VKA) have been the standard of care
for stroke prevention in atrial fibrillation, as well as venous
thromboembolism (VTE) prevention and treatment. Given
their narrow therapeutic index, close monitoring using the
international normalization ratio (INR) is warranted.
The introduction of Direct Oral Anticoagulants (DOACs)
in the past decade was a game-changer. DOACs are oral
alternatives to Warfarin with a lower risk of bleeding that do
not require recurrent blood draw for INR monitoring, and
1 has a quicker onset of action. Also, DOACs are beneficial
in minimizing the confusion caused by the baseline elevated
INR in patients with cirrhosis. The direct thrombin inhibitor
Dabigatran, factor Xa inhibitors, Rivaroxaban, Apixaban,
and Edoxaban were all approved for the treatment and
prevention of VTE and the prevention of stroke in patients
with nonvalvular atrial fibrillation. Several clinical trials
aimed to evaluate the effectiveness and safety of DOACs
compared to VKA in stroke prevention in atrial fibrillation
and in the treatment of VTE. Compared to VKA, DOACs

were shown to be noninferior in the treatment of VTE (reference). Dabigatran and Apixaban were shown to be superior
to Warfarin in preventing strokes in patients with atrial
fibrillation (reference). Compared to Warfarin, Rivaroxaban
and Edoxaban were noninferior in preventing strokes in
atrial fibrillation patients [1–6]. Other indications for DOACs
include cancer associated thrombosis, secondary prevention
of major cardiovascular disease in patients with acute coronary syndrome, prophylaxis of VTE in acutely ill hospitalized
patients, and long-term management of ACS [7–10].
So far, most of the randomized clinical trials studying
DOACs have excluded patients with remarkable liver disease and cirrhosis. The rationale behind cirrhosis being an
exclusion criterion goes back to the complex hemostasis
in patients with liver cirrhosis. As a result of hepatic dysfunction, patients have a “rebalanced hemostasis” leading
to both procoagulant and anticoagulant effects [11]. Though
patients with cirrhosis might have a prolonged INR and
thrombocytopenia, studies showed an increased risk of VTE
in this patient population [12]. Sogaard et al. found a 1.7-fold
higher relative risk of VTE in cirrhotic patients compared to
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healthy controls. On the other hand, in cirrhotics, especially
those with large varices or varices with red wale sign, variceal
bleeding remains a substantial concern [13, 14]. Nowadays,
given the lack of high-level evidence, common practice is
to assess the individual risks and benefits of anticoagulation
when indicated in this subset of patients.
Of all anticoagulants available, low molecular weight
heparin (LMWH) and Warfarin with INR target between
2 and 3 were the most studied and used in patients with
cirrhosis. The use of DOACs in patients with cirrhosis is still
not a common practice given the limited data about their
efficacy and safety in this special population [15]. The aim
of this review article is to discuss the current evidence of
potential indications and safety of DOACs use in patients
with liver cirrhosis.

2. Hemostasis in Liver Disease
Several defects account for the altered hemostasis in patients
with liver disease. A recent study concluded that cirrhotic
patients have an overall procoagulant state but a decreased
clot formation capacity and an unaltered resistance to clot
lysis [16]. Most reported hemostatic abnormalities are related
to the production of pro-, and anticoagulation factors, the
associated thrombocytopenia and platelet dysfunction, and
the increased fibrinolysis.
2.1. Coagulation Factors Defects. The liver is the site of production of almost all coagulation factors (factors I, II, V, VII,
IX, X, XI, and XII) except factors VIII which are produced
in endothelial cells, and factor XIII which is produced in
the bone marrow. With cirrhosis, there is a defect in the
production of most factors that is reflected by a prolonged
prothrombin time (PT) and activated partial thromboplastin
time (aPTT) [17].
2.2. Thrombocytopenia. Patients with liver disease might
have varying degrees of thrombocytopenia. In this population, three major mechanisms account for thrombocytopenia
including impaired platelet production due to decrease hepatic synthesis of thrombopoietin, bone marrow suppression
from infections and/or alcohol use, and increased platelet
sequestration in the spleen [18].
2.3. Increased Fibrinolysis. Contributors to increased fibrinolysis in chronic liver disease patients are the increased level
of tissue plasminogen activator (TPA) and the elevated levels
of fibrin degradation products. This is possibly a result of
the small number of hepatocytes and Kupffer cells which are
thought to clear coagulation factors and fibrinolysis products
from the circulation [19]. In addition, ascitic fluid which
has a high fibrinolytic activity might drain via the thoracic
duct to the systemic circulation contributing to the altered
hemostasis [20, 21].
2.4. Prothrombotic Changes. The liver also synthesizes endogenous anticoagulation factors like protein C, protein S,
and antithrombin III, as well as fibrinolytic factors which
are not measured by routine blood assays. Moreover, the
cirrhotic liver cannot clear von Willebrand Factor (vWF)
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which further adds to the prothrombotic effects of cirrhosis
(reference).

3. Venous Thromboembolism (VTE) and
Portal Vein Thrombosis (PVT) Prophylaxis
in Patient with Liver Cirrhosis
Studies have demonstrated a 0.5-6.3% incidence of newly
diagnosed DVT and PE among hospitalized patients with
liver cirrhosis, a rate that is not different from that of patients
without cirrhosis [22, 23]. Apart from venous thromboembolism, common thrombotic events affecting patients with
liver disease are splanchnic vein thromboses including portal
and hepatic vein thrombosis. Portal vein thrombosis (PVT)
occurs in 8-25% of patient with decompensated liver cirrhosis
as compared to only 1% of patients with compensated liver
cirrhosis [23].
3.1. VTE Prophylaxis. The relationship between prophylactic
anticoagulation and VTE in cirrhotics is controversial. While
some studies showed lower incidence of VTE in patients
treated with prophylactic anticoagulation [24], others failed
to show any difference between nonrecipients and recipients
of any form of prophylactic anticoagulation (mechanical or
pharmacologic) [25]. However, prophylactic anticoagulation
is appropriate for medical and surgical patients with liver
cirrhosis after VTE risk factor assessment as studies showed
no significant increase in the risk of bleeding in this patient
category [24–26]. The VTE risk assessment in such patients
can be performed using models such as the Padua prediction
score [27], with exceptions to the use of prophylaxis being
an overall low risk of VTE, severe thrombocytopenia, active
bleeding, and high-risk varices. The treating physician’s
clinical judgment should take into consideration the abovementioned data before starting VTE prophylaxis.
3.2. PVT Prophylaxis. PVT prophylaxis in patients with
liver disease is not routinely used in clinical practice. A
randomized clinical trial was done to assess the role of anticoagulation in the prevention of PVT. The RCT concluded
that enoxaparin was safe and effective in preventing PVT in
cirrhotic patients with a Child Turcotte Pugh (CTP) score
of 7-10. PVT prophylaxis with enoxaparin appeared to delay
the occurrence of hepatic decompensation and improve the
transplant free survival [28].

4. Treatment Options for Thrombotic Diseases
in Patients with Liver Cirrhosis
4.1. VTE. There is no consensus on the safety, monitoring,
and efficacy of full dose anticoagulation to treat VTE in
patients with liver cirrhosis. A general practice is to find a
balance between the risks and benefits of anticoagulation.
The risk of variceal bleeding is by far the most concerning
potential complication in this patient population. In patient
with increased risk of bleeding, treatment is controversial
and anticoagulation should be avoided. Currently, in patients
at low risk of bleeding, Warfarin is more often used than
DOACs due to the lack of evidence on safety and efficacy
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of DOACs in this scenario. The choice and duration of
therapy are usually based on a team-based decision between
consultants [15, 26, 29].
4.2. Atrial Fibrillation Therapy. Data for anticoagulation in
patients with atrial fibrillation and liver cirrhosis is also
scanty. Ling Kuo et al. showed that the risk of ischemic stroke
was lower in cirrhotic patients and atrial fibrillation treated
with Warfarin, compared to patients receiving antiplatelet
therapy or those untreated. On the other hand, the risk
of intracranial hemorrhage (ICH) was similar between the
three groups of patients. This reflects a net clinical benefit
for Warfarin treatment in patients with cirrhosis and atrial
fibrillation [30].
4.3. PVT Therapy. Patient with PVT in cirrhosis might
experience spontaneous complete recanalization [31]. However, a number of studies have shown better rates of portal
vein recanalization in patients treated with low molecular
weight heparin or Warfarin compared to those who did not
receive treatment, but without evidence of mortality benefit.
Complete recanalization of the portal vein resulted in a
trend towards less episodes of hepatic encephalopathy and
lower rate of complications due to portal hypertension [32].
Senzolo et al. showed that, in patients with PVT treated with
LMWH, lower rates of bleeding were reported with a ratio
of one to five compared to patients that were left untreated
[33]. Similarly, a recent meta-analysis from Italy compiled
results of 8 RCTs with a total of 353 cirrhotic patients with
PVT and showed a substantial benefit of anticoagulation
with conventional agents. Patients with cirrhosis and PVT
who received anticoagulation had significantly higher rates
of recanalization and reduced clot progression, a significantly
lower incidence of variceal bleeds, and a similar incidence
of minor and major nonvariceal bleeding events compared
to those who did not receive treatment [34]. Another two
studies have suggested that LMWH is safe and effective in the
treatment of PVT in patient with liver cirrhosis [35, 36]. Data
about the role of DOACs in the treatment of cirrhotic PVT
is limited. Several case reports indicated that Rivaroxaban
and Apixaban may be used to treat PVT; however, their
efficacy was reduced [37]. In a recent retrospective study,
Nagaoki Y et al. evaluated PVT in fifty cirrhotic patients with
variable CTP scores (CTP A: n = 29; CTP B: n = 16; CTP
C: n = 5) that were treated with danaparoid sodium for two
weeks and then randomized to receive either Warfarin or
Edoxaban for a total of 6 months. Thirty patients received
Warfarin with a target INR between 1.5 and 2, and 20 patients
received Edoxaban that was dose adjusted to weight and
creatinine clearance. The PVT volume was measured by
dynamic computed tomography before, and periodically during treatment. After 6 months, the volume of PVT in patients
treated with Edoxaban decreased from 1.42 cm3 to 0.42 cm3 ,
signaling effective anticoagulation. Conversely, PVT volume
was significantly higher after 6 months of treatment with
Warfarin, increasing from 1.7 cm3 up to 2.85 cm3 . As for the
safety of anticoagulation, gastrointestinal bleeding occurred
in 3 patients in the Edoxaban group compared to 2 patients
in the Warfarin group. There was no significant difference
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among the two study arms regarding GI bleeding or any other
adverse effects. Bleeding was successfully controlled in all
patients using mechanical or pharmacological treatments. In
addition, it is important to notice that none of the patients
with CTP B developed GI bleed which can be an indicator
that Edoxaban is possibly safe, specifically in this patient
group. The same conclusion cannot be generalized to patients
with CTP C, since none of the patients in this category
received Edoxaban [38]. The results and the clinical utility of
this study should be interpreted with caution, since the target
INR was between 1.5 and 2, rather than the standard target
between 2 and 3.

5. Classic Anticoagulants in Patients with
Liver Cirrhosis
In general, Heparin and LWMH function by potentiating the
effect of antithrombin, which then inactivates several serial
proteases, thus preventing the conversion of fibrinogen to
fibrin (Figure 1).
Unfractionated heparin (UFH) potentiates the effect of
antithrombin which inactivates thrombin (IIa) and other
clotting factors (IX, X, XI, XII, and plasmin) and prevents the
conversion of fibrinogen to fibrin.
LMWH also potentiates the effect of antithrombin to
inactivate mainly factor Xa rather than thrombin (IIa) and
subsequently prevent the conversion of fibrinogen to fibrin.
The effect of heparin in patients is monitored using the
aPTT with a target prolongation of 1.5-2.5 times that of
controls. Nonetheless, the decrease in antithrombin levels in
patients with chronic liver disease may lead to falsely elevated
aPTT, resulting in an undesired confusion over therapeutic
levels in patients on heparin therapy. Alternatively, no routine
monitoring is required for LMWH which is thought to
carry a lower bleeding risk than unfractionated heparin in
patients with cirrhosis. The latter is probably due to the
higher sensitivity of cirrhotics to heparin [26]. When a
prophylactic dose of enoxaparin was given for 48 weeks for
prevention of PVT in patients with CTB class B and C, no
increase in bleeding events was noticed compared to placebo
[26]. Additionally, when therapeutic doses were given for
long-term treatment of PVT, the risk of bleeding was not
significantly increased [22, 23]. In comparison, therapeutic
doses of heparin resulted in a significant drop in hemoglobin
and platelets [39]. The advantage of anticoagulation with
heparin derivatives is the availability of protamine sulfate as a
reversal agent. Heparin and LWMH are to be withheld 4 and
12 hours respectively, prior to an invasive procedure.
Danaparoid sodium is an IV heparinoid agent that acts
by inactivating factor Xa and thrombin. It is indicated for
treatment of DVT and PE and can be used as a substitute
for heparin in heparin induced thrombocytopenia. It has a
comparatively lower bleeding risk and higher anticoagulant
effect than heparin [40, 41]. In patients with liver cirrhosis,
danaparoid sodium was found to be both, effective and
relatively safe in treating PVT as it had no significant bleeding
events when used for two weeks [42].
VKAs work by the inhibition of the synthesis of vitamin
K dependent clotting factors II, VII, IX and X (Figure 1).
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Xa Inhibitors (Rivaroxaban,
Apixaban, Edoxaban)

XII

XIIa
XI

XIa
IX

Warfarin

Tissue factor

IXa
Xa

X
II (Prothrombin)

VII

VII-TF

Warfarin

Heparin + antithrombin III

IIa (Thrombin)

IIa inhibitors (Dabigatran)

Ia Fibrin

I(Fibrinogen)
XIIIa
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Figure 1: The effect on anticoagulants on the coagulation cascade.

Reversal agents include vitamin K, prothrombin complex
concentrate (PCC), and fresh frozen plasma (FFP) in the
setting were (PCC) is not available. Warfarin is stopped 5 days
before any invasive procedure to prevent bleeding.
The baseline prolonged INR in liver cirrhosis leads to
some controversy in initiating Warfarin on cirrhotic patients.
According to current guidelines, the target therapeutic INR
should be between 2 and 3 [43]. There are limited studies
that assess the safety and efficacy of this approach in patients
with cirrhosis. A recent study of 23 patients with liver
cirrhosis showed that a target INR of 2-3 can be reached
with Warfarin doses similar to those in noncirrhotic patients.
The reduction of endogenous-thrombin-potential (ETP) was
shown to reflect the effect of LMWH and Warfarin, and has
been recently considered a potential monitoring parameter
for anticoagulation in liver cirrhosis [44].

6. Direct Oral Anticoagulants (DOACs) in
Patients with Liver Cirrhosis
DOACs were developed to inhibit specific targets in the coagulation cascade. They are administered at fixed doses adjusted
to kidney function, and routine monitoring for INR is not
indicated. Indications for DOACs use include but are not
limited to VTE prevention and treatment, stroke prevention
in nonvalvular atrial fibrillation, and VTE prophylaxis after
hip/knee surgeries. In the meantime, the approved DOACs
in United States are three direct factor Xa inhibitors and
one direct factor IIa inhibitor. DOACs represent a double
challenge in patients with cirrhosis, first because of the
impairment of the coagulation cascade, and second because
of the possible effect of liver injury on drug metabolism. The
hepatic elimination of Apixaban, Rivaroxaban, Edoxaban,
and Dabigatran is 75%, 65%, 50%, and 20% respectively [45]
(Table 1). Accordingly, the alteration of cytochrome P450
mediated metabolism, plasma protein binding, biliary secretion, and hepatorenal syndrome in patient with liver injury
affect DOACs pharmacokinetics to various degrees. Child
Pugh classification is recommended to assess the degree
of hepatic injury and to determine the dosing of DOACs
thereafter (Figure 2). On the other hand, the effect of DOACs
on the liver in terms of liver injury adds to the complexity

Table 1: Route of elimination of DOACSs.
DOAC
Apixaban
Rivaroxaban
Edoxaban
Dabigatran

Liver elimination
75%
65%
50%
20%

Renal elimination
25%
35%
50%
80%

of the picture. Early clinical trials showed that Ximelagatran
(factor IIa inhibitor) resulted in significant hepatotoxicity
and subsequently the drug was withdrawn from the market.
A following meta-analysis with more than 29 randomized
controlled trials showed that the currently used DOACs have
no significant risk of drug-induced liver injury [46].
Nonetheless, as experience with DOACs nurtures, there
is accumulating evidence that the usage of DOACs is promising in cirrhotic patients in terms of efficacy and safety.
Andexanet is a new medication that was recently US FDA
approved in May 2018 for the reversal of anticoagulation by
Rivaroxaban or Apixaban in life threatening and uncontrolled
bleeding [47, 48]. New studies that are being conducted for
DOACs antidotes will add more substratum to the use of
DOACs in cirrhotic patients. Among the latest encouraging
results, Idarucizumab to reverse the effect of Dabigatran
and Ariprazine appears to reverse the effect of DOACs
immediately after infusion [49, 50].
6.1. Dabigatran. 1.5% to 3% of patients treated with Dabigatran have more than 3-fold rise in aminotransferase. This rate
is similar to rates with Warfarin and lower than the rates with
LMWH. Rare cases of jaundice and clinically apparent liver
injury secondary to Dabigatran have been reported, but these
cases were usually mild and self-limited [4, 51].
The approved prescribing guidance for Dabigatran does
not include any specific recommendations for usage or dosing
in patients with hepatic dysfunction [52]. An in vitro study
compared the effect of Dabigatran on thrombin generation
assays in healthy controls compared to cirrhotic patients’
plasma. The addition of Dabigatran to cirrhotic patients’
plasma resulted in a more pronounced anticoagulation effect
compared to controls. In addition, higher reductions in
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Bleeding risk assessment by endoscopy

No varices

No intervention

Medium or Large Varices

Small varices

High risk

Low risk

High risk

Low risk

CTP B and C
Red wale sign

CTP A
No red wale sign

CTP B and C
Red wale sign

CTP A
No red wale sign

Beta blocker
recommended

Beta blocker
can be used

Beta blocker
or EVL

Beta blocker
preferred to EVL

If anticoagulation is indicated:

Follow FDA recommendations after CTP classification
(Table 2)

Figure 2: Recommended algorithm for DOACs therapy initiation in cirrhosis. CTP: Child Turcotte Pugh score. EVL: Endoscopic Variceal
Ablation (see Table 2).
Table 2: FDA recommendation for DOACs usage in liver disease according to Child-Pugh class.
Child-Pugh class A
Dabigatran (no dose adjustment)
Apixaban (no dose adjustment)
Edoxaban (no dose adjustment)
Rivaroxaban (no dose adjustment)

Child-Pugh class B
Use with caution (no dose adjustment)
Use with caution (no dose adjustment)
Not recommended
Not recommended

thrombin generation time, reflecting a higher anticoagulation
effect, seemed to be associated with cirrhosis severity, being
highest in CTP C patients [53]. However, another in vivo
study examining the effect of a single dose of Dabigatran 150 mg in healthy controls and patients with CTP B
showed no difference in drug exposure or coagulation indices
between the two groups [54].
6.2. Rivaroxaban. 1.5% to 3% of patients treated with
Rivaroxaban have more than 3-fold rise in aminotransferase,
a rate that is similar to that of Warfarin and lower than that
of LMWH. Rivaroxaban has been related to several instances
of acute liver injury with jaundice, both hepatocellular and
cholestatic or mixed patterns of liver injury have been
reported. All reported cases of liver injury recovered after
stopping Rivaroxaban [3, 55].
Rivaroxaban is not recommended for use in patients with
CTP B or C cirrhosis or any liver disease associated with
coagulopathy as per its approved guidance prescription [53,
56]. However, different studies have shown varying outcomes.
A small study that evaluated the effect of Rivaroxaban in
healthy controls compared to patients with varying degrees of
hepatic disease excluding CTP C patients, revealed increased
drug exposure in patients with CTB B cirrhosis relative to
those with CTP A and healthy controls [57]. Alternatively,
the in vitro study by Potze et al. demonstrated no difference

Child-Pugh class C
Not recommended
Not recommended
Not recommended
Not recommended

in anticoagulation effect between healthy controls, CTP A
or B cirrhosis. More so, Rivaroxaban resulted in a reduced
anticoagulant effect in CTP C patients compared to controls,
CTP A, and B patients [53]. One case reported that Rivaroxaban was safe and effective for the treatment of PVT in a
patient with CTP A cirrhosis [58]. A case series examined 20
cirrhosis patients, nine of which received Rivaroxaban while
eleven received Apixaban for PVT, VTE or stroke prophylaxis
in atrial fibrillation. Outcomes were compared to a cohort
study of traditional anticoagulation. The study showed no
difference in the rates of major bleeding between the DOACs
and the conventional anticoagulation arms [26]. To sum up,
more clinical studies are needed to reach a conclusion about
the efficacy and safety of DOACs in cirrhotic patients.
6.3. Apixaban. 1% to 2% of patients treated with Apixaban
have more than 3-fold rise in aminotransferase mainly in
hepatocellular pattern; this rate is similar or lower than rates
with Warfarin [59].
Apixaban requires no dose adjustment in patients with
CTP A cirrhosis. While no specific recommendation is available for patients with CTP B cirrhosis, Apixaban is not recommended in patients with CTP C according to its approved
prescribing guidance [60]. As mentioned previously, in the
case series by Intagliata et al. 11 out 20 patients received
Apixaban therapy for PVT, VTE, or stroke prophylaxis
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in atrial fibrillation. Similar rates of major bleeding events
were observed between DOACs users and patients on conventional anticoagulation [26].
A recent small case series including CTP A patients
showed that Apixaban may be safe and effective for selected
patients with PVT [15].
6.4. Edoxaban. 2% to 5% of patients treated with Edoxaban
have more than 3-fold rise in aminotransferase. The rate
is similar or lower than rates with Warfarin [2]. While no
dose adjustment is necessary for Edoxaban use in patients
with CTP A cirrhosis, the drug is not recommended in
patients with CTP B and C [61]. A recent study examining the
metabolism of one single dose of Edoxaban 15 mg in patients
with CTP A and B found no difference in drug exposure
between the 2 groups [62]. Large clinical trials including a
more prolonged drug exposure are needed to further clarify
the safety and efficacy of Edoxaban in patients with moderate
to severe cirrhosis.

7. DOACs versus Traditional Anticoagulation
in Patients with Liver Cirrhosis
To date, a limited number of clinical studies compared
DOACs to traditional anticoagulation in patients with liver
cirrhosis. One observational study on patients with cirrhosis
compared 20 patients on DOACs to 19 patients on conventional anticoagulation therapy over a 3-year period. Among
patients on DOACs therapy, 11 received Apixaban and 9
patients received Rivaroxaban. In comparison, 13 patients
received VKA, and 6 patients received LMWH as traditional
anticoagulation agents. The rate of any bleeding event was
not significantly different between the two groups. Two major
bleeding events occurred in the traditional anticoagulation
group compared to one event in the DOACs group. The study
concluded that DOACs have similar safety characteristics
compared to traditional anticoagulation in patients with
cirrhosis [26]. It is noteworthy to mention that in addition to
its small sample size, this study only included CTP A and B
patients and consequently, its results cannot be extrapolated
to patients with CTP score C. The study’s results are also
in concordance with those of a meta-analysis suggesting
no increased risk of drug-induced liver injury with DOACs
use compared to conventional anticoagulation [46]. Another
retrospective cohort study looked at cirrhotic patients with
anticoagulation prescriptions for VTE treatment or stroke
prophylaxis in atrial fibrillation. The study spanned over
a 3-year period during which, 27 patients were prescribed
DOACs (Rivaroxaban or Apixaban) and 18 participants were
prescribed VKA and LMWH. Both groups had similar
total bleeding events, however, there were significantly less
major bleeding episodes in the DOACs group. Remarkably,
compared to DOACs, traditional anticoagulation had a
shorter time interval between initiation of therapy and a
major bleeding event. While both groups had similar rates
of gastrointestinal bleeding, three intracranial hemorrhage
events occurred in the traditional anticoagulation arm while
none took place in DOACs recipients. Otherwise, the rate
of recurrent thrombosis was similar between both DOACs
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and traditional therapy groups, accounting to 1 event in
each arm [29]. Despite the study’s conclusion that DOACs
were as effective as traditional anticoagulation agents with
a better safety profile, there were major limitations worth
noting such as the retrospective design of the study, its small
sample size, and the limited number of CTP C patients (six)
which restricted the applicability of those results in everyday
practice.

8. Conclusion
DOACs are a breakthrough therapy for patients requiring
anticoagulation. Among potential therapeutic advantages in
cirrhotic patients, the benefits of DOACs include their quick
onset of action, their simple dosage, and the fact that they
do not need INR monitoring, thus sparing patients repeated
laboratory testing and avoiding confusion in light of the existing altered coagulation parameters associated with cirrhosis.
Still, the usage of DOACs in patients with cirrhosis must be
evaluated on a case by case basis. To decrease the risk of
possible bleed, control of underlying varices if present is to be
attempted (Figure 2). To date, the indications to use DOACs
in specific patient populations including cirrhotics are still
an area of debate and further research. The majority of the
available data is still considerably conflicting; however, results
of trials in noncirrhotic patients are promising and suggest
potential new indications for DOACs use. In summary, the
evidence for safe use of DOACs in patients with hepatic
impairment is still murky. Randomized controlled trials are
needed to examine the efficacy, pharmacodynamics, and
safety of DOACs especially in moderate to severe cirrhosis.
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[28] E. Villa, C. Cammà, M. Marietta et al., “Enoxaparin prevents
portal vein thrombosis and liver decompensation in patients
with advanced cirrhosis,” Gastroenterology, vol. 143, no. 5, pp.
1253–1260, 2012.
[29] J. Hum, J. J. Shatzel, J. H. Jou, and T. G. Deloughery, “The
efficacy and safety of direct oral anticoagulants vs traditional
anticoagulants in cirrhosis,” European Journal of Haematology,
vol. 98, no. 4, pp. 393–397, 2017.
[30] L. Kuo, T. F. Chao, C. J. Liu, Y. J. Lin, S. L. Chang, L. W. Lo
et al., “Liver cirrhosis in patients with atrial fibrillation: would
oral anticoagulation have a net clinical benefit for stroke prevention?” Journal of the American Heart Association, vol. 6, no. 6,
2017.
[31] F. Nery, S. Chevret, B. Condat et al., “Causes and consequences
of portal vein thrombosis in 1,243 patients with cirrhosis: results
of a longitudinal study,” Hepatology, vol. 61, no. 2, pp. 660–667,
2015.
[32] M. G. Delgado, S. Seijo, and I. Yepes, “Efficacy and safety
of anticoagulation on patients with cirrhosis and portal vein
thrombosis,” Clinical Gastroenterology and Hepatology, vol. 10,
no. 7, pp. 776–783, 2012.
[33] M. Senzolo, T. M. Sartori, V. Rossetto et al., “Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in
cirrhosis,” Liver International, vol. 32, no. 6, pp. 919–927, 2012.
[34] L. Loffredo, D. Pastori, A. Farcomeni, and F. Violi, “Effects of
anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis,” Gastroenterology,
vol. 153, no. 2, pp. 480.e1–487.e1, 2017.
[35] L. Amitrano, M. A. Guardascione, A. Menchise et al., “Safety
and efficacy of anticoagulation therapy with low molecular
weight heparin for portal vein thrombosis in patients with liver
cirrhosis,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp.
448–451, 2010.
[36] C. Francoz, J. Belghiti, V. Vilgrain et al., “Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of
screening and anticoagulation,” Gut, vol. 54, no. 5, pp. 691–697,
2005.

8
[37] W. Potze, J. Adelmeijer, and T. Lisman, “Decreased in vitro
anticoagulant potency of Rivaroxaban and Apixaban in plasma
from patients with cirrhosis,” Hepatology, vol. 61, no. 4, pp. 14351436, 2015.
[38] Y. Nagaoki, H. Aikata, K. Daijyo et al., “Efficacy and safety of
edoxaban for treatment of portal vein thrombosis following
danaparoid sodium in patients with liver cirrhosis,” Hepatology
Research, vol. 48, no. 1, pp. 51–58, 2018.
[39] A. Fuentes, S. Gordon-Burroughs, J. B. Hall, D. R. Putney, and
H. P. Monsour, “Comparison of anti-xa and activated partial
thromboplastin time monitoring for heparin dosing in patients
with cirrhosis,” Therapeutic Drug Monitoring, vol. 37, no. 1, pp.
40–44, 2015.
[40] P. M. J. Hobbelen, G. M. T. Vogel, and D. G. Meuleman, “Time
courses of the antithrombotic effects, bleeding enhancing effects
and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin
to rats,” Thrombosis Research, vol. 48, no. 5, pp. 549–558, 1987.
[41] D. G. Meuleman, “Orgaran (Org 10172): Its pharmacological
profile in experimental models,” Pathophysiology of Haemostasis
and Thrombosis, vol. 22, no. 2, pp. 58–65, 1992.
[42] N. Naeshiro, H. Aikata, H. Hyogo, H. Kan, H. Fujino, T.
Kobayashi et al., “Efficacy and safety of the anticoagulant drug,
danaparoid sodium, in the treatment of portal vein thrombosis
in patients with liver cirrhosis,” Hepatology Research, vol. 45, no.
6, pp. 656–662, 2015.
[43] European Association for the Study of the Liver, “EASL clinical
practice guidelines: vascular diseases of the liver,” Journal of
Hepatology, vol. 64, no. 1, pp. 179–202, 2016.
[44] A. Tripodi, M. Primignani, S. Braham et al., “Coagulation parameters in patients with cirrhosis and portal vein thrombosis
treated sequentially with low molecular weight heparin and
vitamin K antagonists,” Digestive and Liver Disease, vol. 48, no.
10, pp. 1208–1213, 2016.
[45] A. Qamar, M. Vaduganathan, N. J. Greenberger, and R. P. Giugliano, “Oral anticoagulation in patients with liver disease,” Journal of the American College of Cardiology, vol. 71, no. 19, pp.
2162–2175, 2018.
[46] D. Caldeira, M. Barra, A. T. Santos et al., “Risk of drug-induced
liver injury with the new oral anticoagulants: Systematic review
and meta-analysis,” Heart, vol. 100, no. 7, pp. 550–556, 2014.
[47] https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606687.pdf.
[48] D. M. Siegal, J. T. Curnutte, S. J. Connolly, G. Lu, P. B. Conley,
B. L. Wiens et al., “Andexanet alfa for the reversal of factor xa
inhibitor activity,” The New England Journal of Medicine, vol.
373, no. 25, pp. 2413–2424, 2015.
[49] J. H. Levy, J. Douketis, and J. I. Weitz, “Reversal agents for
non-vitamin K antagonist oral anticoagulants,” Nature Reviews
Cardiology, vol. 15, no. 5, pp. 273–281, 2018.
[50] J. E. Ansell, S. H. Bakhru, B. E. Laulicht et al., “Use of PER977 to
reverse the anticoagulant effect of edoxaban,” The New England
Journal of Medicine, vol. 371, no. 22, pp. 2141-2142, 2014.
[51] B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran
etexilate vs. subcutaneous enoxaparin for the prevention of
venous thromboembolism after total knee replacement: the REMODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007.
[52] Pradaxa (dabigatran etexilate), [package insert], Boehringer
Ingelheim Pharmaceuticals Inc., Ridgefield, California, Calif,
USA, 2015.

Canadian Journal of Gastroenterology and Hepatology
[53] W. Potze, F. Arshad, J. Adelmeijer et al., “Differential in vitro
inhibition of thrombin generation by anticoagulant drugs in
plasma from patients with cirrhosis,” PLoS ONE, vol. 9, no. 2,
Article ID e88390, 2014.
[54] J. Stangier, H. Stähle, K. Rathgen, W. Roth, and K. ShakeriNejad, “Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected
by moderate hepatic impairment,” Clinical Pharmacology and
Therapeutics, vol. 48, no. 12, pp. 1411–1419, 2008.
[55] H. R. Büller, M. H. Prins, A. W. Lensin et al., “Oral rivaroxaban
for the treatment of symptomatic pulmonary embolism,” New
England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012.
[56] Xarelto (rivaroxaban), [package insert], Janssen Pharmaceuticals Inc., Titusville, New Jersey, NJ, USA, 2015.
[57] D. Kubitza, A. Roth, M. Becka et al., “Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a
single dose of rivaroxaban, an oral, direct Factor Xa inhibitor,”
British Journal of Clinical Pharmacology, vol. 76, no. 1, pp. 89–98,
2013.
[58] M. Martinez, A. Tandra, and R. Vuppalanchi, “Treatment of
acute portal vein thrombosis by nontraditional anticoagulation,” Hepatology, vol. 60, no. 1, pp. 425-426, 2014.
[59] C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban
versus warfarin in patients with atrial fibrillation,” The New
England Journal of Medicine, vol. 365, no. 11, pp. 981–992, 2011.
[60] Eliquis (apixaban), [package insert], Bristol-Myers Squibb, New
York, NY, USA.
[61] Savaysa (edoxaban), [package insert], Daiichi Sankyo, Tokyo,
Japan.
[62] J. Mendell, L. Johnson, and S. Chen, “An open-label, phase 1
study to evaluate the effects of hepatic impairment on edoxaban
pharmacokinetics and pharmacodynamics,” Journal of Clinical
Pharmacology, vol. 55, no. 12, pp. 1395–1405, 2015.

